Review
Medicine, General & Internal
Mikkael A. Sekeres, Justin Taylor
Summary: MDS is a hematopoietic malignancy with bone marrow dysplasia and decreased blood cell numbers. Treatment varies based on disease characteristics, from supportive care to hypomethylating agents for high-risk patients. Hematopoietic cell transplantation is potentially curative for high-risk MDS.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2022)
Article
Multidisciplinary Sciences
Nanfang Huang, Yang Song, Wenhui Shi, Juan Guo, Lingyun Wu, Zheng Zhang, Qi He, Xiao Li, Feng Xu
Summary: DHX9 overexpression in myelodysplastic syndromes (MDS) is associated with poor prognosis and high risk of acute myeloid leukemia (AML) transformation. DHX9 is essential for malignant proliferation of leukemia cells. Suppression of DHX9 increases cell apoptosis and sensitizes cells to chemotherapy. Additionally, DHX9 knockdown inactivates PI3K-AKT and ATR-Chk1 signaling, promotes R-loop accumulation, and leads to R-loop-mediated DNA damage.
Article
Oncology
Tine Bichel Lauritsen, Jan Maxwell Norgaard, Susanne Oksbjerg Dalton, Kirsten Gronbaek, Tarec Christoffer El-Galaly, Lene Sofie Granfeldt ostgard
Summary: This study examined 10-year trends in incidence, treatment patterns, and all-cause mortality in a population-based cohort of 2309 MDS patients. The study found a slight increase in the incidence of MDS and a significant increase in the use of azacitidine, but five-year overall survival remained unchanged.
Review
Medicine, General & Internal
Yannick Simoni, Nicolas Chapuis
Summary: Myelodysplastic syndromes (MDS) are a heterogeneous group of diseases with a high prevalence in elderly patients, and a tendency to progress to acute myeloid leukemia. Immune dysregulations play a critical role in the pathogenesis of MDS, and monitoring the immune system can help in precise diagnosis and identifying patients who may benefit from immunotherapy.
Article
Hematology
Guillermo Garcia-Manero
Summary: The myelodysplastic syndromes (MDS) are a group of myeloid disorders characterized by low blood cell counts and increased risk of developing acute myelogenous leukemia (AML). Diagnosis is based on visual examination of bone marrow samples and additional tests such as karyotyping and flow cytometry. Prognosis can be determined using scoring systems like the Revised International Prognostic Scoring System (IPSS-R).
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Oncology
Qiuni Chen, Yue Chen, Yijing Zhang, Lijuan Zhang, Kankan Chen, Zhengmei He, Chunling Wang, Liang Yu
Summary: This study demonstrates that P-LCR can serve as a biomarker to predict the prognosis of MDS patients, which has significant clinical implications.
FRONTIERS IN ONCOLOGY
(2022)
Article
Hematology
Nathan Radakovich, Manja Meggendorfer, Luca Malcovati, C. Beau Hilton, Mikkael A. Sekeres, Jacob Shreve, Yazan Rouphail, Wencke Walter, Stephan Hutter, Anna Galli, Sara Pozzi, Chiara Elena, Eric Padron, Michael R. Savona, Aaron T. Gerds, Sudipto Mukherjee, Yasunobu Nagata, Rami S. Komrokji, Babal K. Jha, Claudia Haferlach, Jaroslaw P. Maciejewski, Torsten Haferlach, Aziz Nazha
Summary: By utilizing clinical and next-generation sequencing data, a machine learning model was successfully developed for the diagnosis of myeloid malignancies independent of bone marrow biopsy data in an international patient cohort, achieving high performance. The model interpretations suggest that it relies on factors similar to those used by clinicians, and associations between NGS findings and clinically important phenotypes were described. The use of machine learning algorithms to elucidate clinicogenomic relationships was also introduced.
Review
Oncology
Andrew M. Brunner, Heather A. Leitch, Arjan A. van de Loosdrecht, Nicolas Bonadies
Summary: This review focuses on the diagnosis, prognosis, and treatment options for patients with lower-risk myelodysplastic syndromes (LR-MDS). It discusses the prediction of disease progression and monitoring of treatment response. The review also explores how next-generation sequencing and novel therapies may impact the treatment landscape for LR-MDS, as well as the importance of incorporating structured assessments into routine clinical practice.
BLOOD CANCER JOURNAL
(2022)
Article
Surgery
Jie Chen, Ying Hang, Qi Gao, Xinyu Huang
Summary: Negative surgical margin and early tumor stage are significantly correlated with the survival of PRPLS patients, while factors like age, gender, and tumor size have insignificant impact. Tumor stage is a critical factor affecting the progression-free survival and overall survival of PRPLS patients.
FRONTIERS IN SURGERY
(2021)
Article
Hematology
Ayalew Tefferi, Farah Fleti, Onyee Chan, Najla H. Al Ali, Aref Al-Kali, Kebede H. Begna, James M. Foran, Talha Badar, Nandita Khera, Mithun Shah, Devendra Hiwase, Eric Padron, David A. Sallman, Animesh Pardanani, Daniel A. Arber, Attilio Orazi, Kaaren K. Reichard, Rong He, Rhett P. Ketterling, Naseema Gangat, Rami Komrokji
Summary: In MDS patients with del(5q), therapy-related setting and TP53 variant allele frequency >=22% were identified as independent risk factors for survival. This information may inform treatment decision-making in MDS-del(5q).
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Silvia Saumell, Miranda Fernandez-Serrano, Alba Mesa, Felix Lopez-Cadenas, Leonor Arenillas, Ana Alfonso, Maria Julia Montoro, Antonieta Molero, Pilar Leoz, Victoria Riego, Laura Gallur, Olga Salamero, Mayda Navarrete, Barbara Tazon-Vega, Margarita Ortega, Oscar Reig, Gael Roue, Xavier Calvo, Felipe Prosper, Maria Diez-Campelo, David Valcarcel
Summary: The presence of Micromegakaryocytes (microMKs) in MDS patients indicates poorer outcomes, including lower overall survival rate and higher risk of progression to AML. Additionally, incorporating microMKs into the IPSS-R score can improve accuracy, leading to reclassification of some patients into higher-risk groups.
LEUKEMIA & LYMPHOMA
(2022)
Review
Hematology
Pongthep Vittayawacharin, Piyanuch Kongtim, Stefan O. Ciurea
Summary: Myelodysplastic syndromes (MDS) are a group of diverse hematopoietic stem cell tumors primarily affecting older individuals, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is currently the only curative treatment. In recent years, the use of reduce-intensity conditioning regimens and haploidentical donors for transplantation has improved treatment outcomes. However, treatment-related mortality remains a limitation, highlighting the importance of pre-transplant evaluation for older patients.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Endocrinology & Metabolism
Manon Belhassen, Eric Van Ganse, Maeva Nolin, Marjorie Berard, Hanane Bada, Eric Bruckert, Michel Krempf, Vinciane Rebours, Rene Valero, Philippe Moulin
Summary: The incidence of acute hypertriglyceridemic pancreatitis was higher in FCS patients compared to MCS patients, while ischemic cardiovascular disease was more common in MCS patients. Both groups had a higher incidence of diabetes compared to controls.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Article
Biochemistry & Molecular Biology
Nehakumari Maurya, Purvi Mohanty, Purvi Panchal, Chandrakala Shanmukhaiah, Babu Rao Vundinti
Summary: Myelodysplastic syndromes (MDS) is a heterogeneous disease characterized by different clinical and biological features. MAPK8, JUNB, and mTOR were found to be significantly upregulated in MDS patients, with MAPK8 and JUNB potentially serving as poor prognostic markers and mTOR as a good prognostic marker.
MOLECULAR BIOLOGY REPORTS
(2023)
Article
Oncology
Hui Liu, Hao Jiang, Hongyan Tong, Ruixiang Xia, Linhua Yang, Hongguo Zhao, Jian Ouyang, Hai Bai, Hui Sun, Li Hou, Ming Jiang, Yun Zeng, Zhuogang Liu, Aibin Liang, Yinghua Xie, Kang Yu, Zhimin Zhai, Li Liu, Jinsong Jia, Rong Fu, Zonghong Shao
Summary: This study compared the efficacy and safety of two different doses of the hypomethylating agent decitabine in patients with intermediate or high risk myelodysplastic syndrome (MDS). The results showed that the 5-day 20-mg/m(2)/day and 8-day 12-mg/m(2)/day decitabine regimens have similar efficacy and safety in treating intermediate or high risk MDS patients.
Article
Hematology
Mrinal M. Patnaik, Daniela Barraco, Terra L. Lasho, Christy M. Finke, Curtis A. Hanson, Rhett P. Ketterling, Naseema Gangat, Ayalew Tefferi
AMERICAN JOURNAL OF HEMATOLOGY
(2017)
Article
Oncology
E. Muchtar, A. Dispenzieri, S. K. Kumar, R. P. Ketterling, D. Dingli, M. Q. Lacy, F. K. Buadi, S. R. Hayman, P. Kapoor, N. Leung, R. Chakraborty, W. Gonsalves, R. Warsame, T. V. Kourelis, S. Russell, J. A. Lust, Y. Lin, R. S. Go, S. Zeldenrust, R. A. Kyle, S. V. Rajkumar, M. A. Gertz
Letter
Oncology
Mohammad Faizan Zahid, Daniela Barraco, Terra L. Lasho, Christy Finke, Rhett P. Ketterling, Naseema Gangat, Curtis A. Hanson, Ayalew Tefferi, Mrinal M. Patnaik
LEUKEMIA & LYMPHOMA
(2017)
Article
Pathology
Joanna G. Newton, John T. Horan, Scott Newman, Michael R. Rossi, Rhett P. Ketterling, Sunita I. Park
PEDIATRIC AND DEVELOPMENTAL PATHOLOGY
(2017)
Article
Oncology
Rachel Barrett, Barbara Morash, David Roback, Chantale Pambrun, Lesley Marfleet, Rhett P. Ketterling, Karen Harrison, Jason N. Berman
PEDIATRIC BLOOD & CANCER
(2017)
Article
Oncology
D. Barraco, S. Cerquozzi, C. A. Hanson, R. P. Ketterling, A. Pardanani, N. Gangat, A. Tefferi
BLOOD CANCER JOURNAL
(2017)
Article
Oncology
M. Binder, S. V. Rajkumar, R. P. Ketterling, P. T. Greipp, A. Dispenzieri, M. Q. Lacy, M. A. Gertz, F. K. Buadi, S. R. Hayman, Y. L. Hwa, S. R. Zeldenrust, J. A. Lust, S. J. Russell, N. Leung, P. Kapoor, R. S. Go, W. I. Gonsalves, R. A. Kyle, S. K. Kumar
BLOOD CANCER JOURNAL
(2017)
Review
Oncology
Prashant Kapoor, Stephen M. Ansell, Rafael Fonseca, Asher Chanan-Khan, Robert A. Kyle, Shaji K. Kumar, Joseph R. Mikhael, Thomas E. Witzig, Michelle Mauermann, Angela Dispenzieri, Sikander Ailawadhi, A. Keith Stewart, Martha Q. Lacy, Carrie A. Thompson, Francis K. Buadi, David Dingli, William G. Morice, Ronald S. Go, Dragan Jevremovic, Taimur Sher, Rebecca L. King, Esteban Braggio, Ann Novak, Vivek Roy, Rhett P. Ketterling, Patricia T. Greipp, Martha Grogan, Ivana N. Micallef, P. Leif Bergsagel, Joseph P. Colgan, Nelson Leung, Wilson I. Gonsalves, Yi Lin, David J. Inwards, Suzanne R. Hayman, Grzegorz S. Nowakowski, Patrick B. Johnston, Steven J. Russell, Svetomir N. Markovic, Steven R. Zeldenrust, Yi L. Hwa, John A. Lust, Luis F. Porrata, Thomas M. Habermann, Vincent Rajkumar, Morie A. Gertz, Craig B. Reeder
Letter
Hematology
Mythri Mudireddy, Sahrish Shah, Terra Lasho, Daniela Barraco, Curtis A. Hanson, Rhett P. Ketterling, Naseema Gangat, Animesh Pardanani, Ayalew Tefferi
BRITISH JOURNAL OF HAEMATOLOGY
(2018)
Article
Hematology
Ayalew Tefferi, Mythri Mudireddy, Naseema Gangat, Curtis A. Hanson, Rhett P. Ketterling, Animesh Pardanani, David M. Nagorney
AMERICAN JOURNAL OF HEMATOLOGY
(2017)
Article
Hematology
Ayalew Tefferi, Silvia Betti, Daniela Barraco, Mythri Mudireddy, Sahrish Shah, Curtis A. Hanson, Rhett P. Ketterling, Animesh Pardanani, Naseema Gangat, Giacomo Coltro, Paola Guglielmelli, Alessandro M. Vannucchi
AMERICAN JOURNAL OF HEMATOLOGY
(2017)
Article
Hematology
Ayalew Tefferi, Terra L. Lasho, Mrinal M. Patnaik, Lyla Saeed, Mythri Mudireddy, Dame Idossa, Christy Finke, Rhett P. Ketterling, Animesh Pardanani, Naseema Gangat
AMERICAN JOURNAL OF HEMATOLOGY
(2017)
Letter
Hematology
Rangit Vallapureddy, Terra L. Lasho, Katherine Hoversten, Christy M. Finke, Rhett Ketterling, Curtis Hanson, Naseema Gangat, Ayalew Tefferi, Mrinal M. Patnaik
AMERICAN JOURNAL OF HEMATOLOGY
(2017)
Article
Hematology
Martin Bjerregard Pedersen, Stephen Jacques Hamilton-Dutoit, Knud Bendix, Rhett P. Ketterling, Patrick P. Bedroske, Ivy M. Luoma, Christopher A. Sattler, Rebecca L. Boddicker, N. Nora Bennani, Peter Norgaard, Michael Boe Moller, Torben Steiniche, Francesco d'Amore, Andrew L. Feldman
Article
Hematology
Mrinal M. Patnaik, Rangit Vallapureddy, Fevzi F. Yalniz, Curtis A. Hanson, Rhett P. Ketterling, Terra L. Lasho, Christy Finke, Aref Al-Kali, Naseema Gangat, Ayalew Tefferi
AMERICAN JOURNAL OF HEMATOLOGY
(2018)
